These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 36920728)

  • 1. Targeting CD43 optimizes cancer immunotherapy through reinvigorating antitumor immune response in colorectal cancer.
    Li YY; Wang XY; Li Y; Wang XM; Liao J; Wang YZ; Hong H; Yi W; Chen J
    Cell Oncol (Dordr); 2023 Jun; 46(3):777-791. PubMed ID: 36920728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition.
    Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer.
    Quan Y; He J; Zou Q; Zhang L; Sun Q; Huang H; Li W; Xie K; Wei F
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer.
    Kim M; Min YK; Jang J; Park H; Lee S; Lee CH
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrinsic β-catenin signaling suppresses CD8
    Xue J; Yu X; Xue L; Ge X; Zhao W; Peng W
    Biomed Pharmacother; 2019 Jul; 115():108921. PubMed ID: 31078045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
    Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
    Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
    Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
    [No Abstract]   [Full Text] [Related]  

  • 9. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
    Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
    Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy.
    Chu XD; Bao H; Lin YJ; Chen RX; Zhang YR; Huang T; He JS; Huangfu SC; Pan YL; Ding H
    Front Immunol; 2022; 13():965492. PubMed ID: 36389685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting m
    Bao Y; Zhai J; Chen H; Wong CC; Liang C; Ding Y; Huang D; Gou H; Chen D; Pan Y; Kang W; To KF; Yu J
    Gut; 2023 Aug; 72(8):1497-1509. PubMed ID: 36717220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCL5-deficiency enhances intratumoral infiltration of CD8
    Zhang S; Zhong M; Wang C; Xu Y; Gao WQ; Zhang Y
    Cell Death Dis; 2018 Jul; 9(7):766. PubMed ID: 29991744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway.
    Zheng X; Luo Y; Xiong Y; Liu X; Zeng C; Lu X; Wang X; Cheng Y; Wang S; Lan H; Wang K; Weng Z; Bi W; Gan X; Jia X; Wang L; Wang Y
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. METTL3 Inhibits Antitumor Immunity by Targeting m
    Chen H; Pan Y; Zhou Q; Liang C; Wong CC; Zhou Y; Huang D; Liu W; Zhai J; Gou H; Su H; Zhang X; Xu H; Wang Y; Kang W; Kei Wu WK; Yu J
    Gastroenterology; 2022 Oct; 163(4):891-907. PubMed ID: 35700773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of CDKN2A is associated with poor prognosis in colorectal cancer and may guide PD-1-mediated immunotherapy.
    Dong Y; Zheng M; Wang X; Yu C; Qin T; Shen X
    BMC Cancer; 2023 Nov; 23(1):1097. PubMed ID: 37950153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
    Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
    J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of the relationship between ubiquitin-specific protease 21 (USP21) and prognosis, tumor microenvironment infiltration, and therapy response in colorectal cancer.
    Nie H; Yu Y; Wang F; Huang X; Wang H; Wang J; Tao M; Ning Y; Zhou J; Zhao Q; Xu F; Fang J
    Cancer Immunol Immunother; 2024 Jun; 73(8):156. PubMed ID: 38834869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling YWHAH: A potential therapeutic target for overcoming CD8
    Li Q; Yuan Z; Wang Y; Zhai P; Wang J; Zhang C; Shao Z; Xing C
    Int Immunopharmacol; 2024 Jun; 135():112317. PubMed ID: 38796965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LOXL1 promotes tumor cell malignancy and restricts CD8 + T cell infiltration in colorectal cancer.
    Li C; Chen S; Fang X; Du Y; Guan XY; Lin R; Xu L; Lan P; Yan Q
    Cell Biol Toxicol; 2024 Jan; 40(1):6. PubMed ID: 38267662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.